MetaCap

Crescent Biopharma (CBIO) vs Climb Bio (CLYM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Climb Bio (CLYM) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 440.6% versus a loss of 0.5%. Over five years, CLYM leads with a -33.2% price change compared with -92.7% for CBIO. Crescent Biopharma is the larger company by market cap ($543.2 million vs $539.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CBIO-0.46%CLYM+440.59%
+998%+459%-81%
Nov 21, 20251 yearNov 20, 2026
CBIO-93.09%CLYM-48.46%
+94%-5%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CBIO versus CLYM key metrics
MetricCBIOCLYM
Share price$13.00$9.19
Market cap$543.21M$539.80M
1-day change+0.70%-0.97%
YTD return+9.61%+129.75%
1-year return-0.46%+440.59%
5-year return-92.74%-33.21%
EPS (TTM)$-7.29$-0.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.84M—
Net income (latest FY)$-153.94M$-59.85M
Operating margin-1407.52%—
Net margin-1419.61%—
52-week high$27.41$18.33
52-week low$8.72$1.64
Distance from 52-week high-52.57%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+148.69%+209.03%
Average volume361.17K1.38M
Shares outstanding38.90M58.74M
Employees8028
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLYM has outperformed CBIO by 441.0 percentage points over the past year.

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Climb Bio

CLYM stock →

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

CBIO vs CLYM FAQ

Which is bigger, Crescent Biopharma or Climb Bio?

Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $539.80M for Climb Bio (CLYM).

Which stock has performed better over the past year, CBIO or CLYM?

CLYM returned +440.59% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.

Are Crescent Biopharma and Climb Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons